A new method for the analysis and production of monoclonal antibody fragments originating from single human B cells
Journal of Immunological Methods, ISSN: 0022-1759, Vol: 207, Issue: 1, Page: 61-67
1997
- 18Citations
- 20Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations18
- Citation Indexes18
- CrossRef18
- 18
- Captures20
- Readers20
- 20
Article Description
The phage display approach has proven to be a major step forward in studies on the human autoimmune repertoire. However, it remains doubtful whether the heavy and light chains of the antibodies obtained from these libraries resemble original in vivo pairings. Here we describe a novel, simple method for the immortalization of the variable heavy and light chain regions originating from individual, nonboosted, autoantigen-specific human B cells. Our method is based on the clonal expansion of B cells in which cell–cell interactions (CD40-CD40L) as well as soluble factors were shown to be essential. This B cell culture system combined with a selection on antigen (the U1A protein, a frequent autoantigenic target in patients with systemic lupus erythematosus) and single cell sorting resulted in the isolation of U1A-specific human B cells and the subsequent expression of an U1A-specific single chain variable fragment (scFv). Our method circumvents laborious plating and screening and has the advantage that original heavy/light chain pairings can be isolated. Due to the high growth efficiency of single cultured B cells (50–70% outgrowth) even rare B cell activities can be studied using this system.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022175997001087; http://dx.doi.org/10.1016/s0022-1759(97)00108-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030865145&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/9328587; http://linkinghub.elsevier.com/retrieve/pii/S0022175997001087; http://api.elsevier.com/content/article/PII:S0022175997001087?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0022175997001087?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S0022175997001087; http://dx.doi.org/10.1016/s0022-1759%2897%2900108-7; https://dx.doi.org/10.1016/s0022-1759%2897%2900108-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know